Frequency of Lipoprotein Analysis
For adults 20 years and older, measure a fasting or nonfasting lipid panel initially, then repeat every 5 years if results are normal and the patient has no cardiovascular risk factors. 1, 2
Adults Without Risk Factors
Initial screening should begin at age 20 years with either a fasting or nonfasting lipid panel (total cholesterol, LDL-C, HDL-C, and triglycerides). 1, 3
Repeat screening every 5 years is appropriate for adults with consistently normal lipid levels and no cardiovascular disease or risk factors. 2, 4
For men aged 20-35 years and women aged 20-45 years without risk factors, screening may be deferred until they reach the age thresholds for routine screening. 2, 4
Adults With Risk Factors or On Treatment
More frequent monitoring is warranted for patients with lipid levels close to treatment thresholds, though specific intervals should be individualized based on proximity to decision points. 2, 4
Patients on lipid-lowering therapy require monitoring at 4-12 weeks after initiation or dose changes, then periodically to assess adherence and efficacy. 2, 5
Adults with diabetes should have lipid profiles obtained at initial evaluation and every 5 years thereafter if LDL-C is within acceptable limits (<100 mg/dL). 6, 2
If lipids are abnormal in diabetic patients, annual monitoring is recommended. 6
Special Populations
Older Adults (>75 years)
Routine lipid testing can be discontinued in adults over 75 years who are not on statin therapy and have no specific cardiovascular risk factors, as the predictive value of cholesterol levels diminishes significantly after this age. 2
Continue monitoring in patients over 75 years who are already on statin therapy, have established atherosclerotic cardiovascular disease, have diabetes with multiple cardiovascular risk factors, or have recently had medication changes. 2
High-Risk Adults
Adults with a family history of premature ASCVD (MI, documented angina, or atherosclerosis in first-degree relatives <55 years for men, <65 years for women) or genetic hyperlipidemia should have a fasting lipid profile measured as part of initial evaluation. 1, 3
For these high-risk individuals, more frequent monitoring may be appropriate, though specific intervals depend on baseline values and treatment status. 1
Children and Adolescents
Selective Screening (High-Risk Children)
Children as young as 2 years should have a fasting or nonfasting lipid profile if they have a family history of early cardiovascular disease or significant hypercholesterolemia in parents (TC ≥240 mg/dL). 7
Children with a parent or grandparent who had cardiovascular disease before age 55 (men) or 65 (women) should be screened with a fasting lipoprotein analysis. 8, 9
Two measurements should be obtained 1-8 weeks apart and averaged due to intraindividual variability before making treatment decisions. 8, 10
Universal Screening
Universal screening once between ages 9-11 years and again between ages 17-21 years may be reasonable for all children without risk factors to detect moderate to severe lipid abnormalities, though this carries a lower strength of recommendation (Class IIb). 7
Screening is NOT recommended for ages 12-16 years in the general population due to significantly decreased sensitivity and specificity for predicting adult LDL-C levels during puberty. 9
Children With Obesity or Metabolic Risk Factors
Children with obesity or other metabolic risk factors should have a fasting lipid profile measured to detect lipid disorders as components of metabolic syndrome. 7
Repeat screening frequency for high-risk children depends on initial results and treatment status, with annual monitoring appropriate for those with abnormal lipids. 6
Fasting vs. Nonfasting Considerations
Nonfasting lipid panels are acceptable for initial screening and monitoring in most adults, as lipid values change minimally (2-5 mg/dL) with normal food intake. 1, 5, 11
Fasting lipid panel is required when initial nonfasting triglycerides are ≥400 mg/dL (≥4.5 mmol/L), as the Friedewald equation for calculating LDL-C becomes inaccurate at this threshold. 1, 3, 5
For children, fasting may not be necessary for initial screening, as studies show only small clinically unimportant differences between fasting and nonfasting values. 12, 13
Common Pitfalls to Avoid
Do not rely on a single lipid measurement for diagnosis or treatment decisions; confirm abnormal results with a repeated sample on a separate occasion and average the results. 4, 10
Do not continue routine screening indefinitely in older adults (>75 years) without cardiovascular disease or treatment, as this provides minimal clinical benefit. 2
Do not screen children aged 12-16 years as part of universal screening protocols, as this age group has poor predictive value for adult lipid levels. 9
Do not assume fasting is always required; for most screening purposes and monitoring on therapy, nonfasting samples are adequate and improve patient compliance and safety, particularly in patients with diabetes at risk for hypoglycemia. 5, 13, 11